Developing a multi-center clinical data mart of ACEI and ARB for real-world evidence (RWE)
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: Randomized controlled trials can be expensive and time-consuming, leading to medical researchers utilizing real-world evidence (RWE) based on already-collected data. We aimed to conduct various RWE studies on angiotensin-converting enzyme inhibitors (ACEI) and angiotensin II receptor blocker (ARB), commonly used as firstline therapy for blood pressure, and to develop a multi-center clinical data mart (CDM) of ACEI/ARB for various clinical purposes. Methods: Data from electronic medical records of St. Mary’s Hospital and the Seoul National University Hospital were collected. We obtained blood and urine test results of patients within the 30 days prior to their first prescription of ACEI or ARB, as well as the first date of diagnosis and presence of various chronic and cardiovascular diseases using the International Classification of Diseases-10 classification. One researcher managed data quality and collation for each hospital in order to facilitate patient anonymity. When results were unclear, the responsible investigator for each hospital attempted to resolve ambiguities by direct chart review. Results: A total of 102,333 patients who were prescribed ACEI or ARB for the first time were included (21,481 ACEI, 80,551 ARB, and 301 both). Our ACEI/ARB-CDM included short-term studies (within 12 months) to observe changes in various blood or urinary laboratory test values after the initial prescription of ACEI or ARB and long-term studies to confirm the incidence of various diseases. Conclusion: We established a CDM of RWE for ACEI/ARB prescription, which included various clinical studies. As we accumulate experience in this process, we expect that the use of RWE research will grow and develop.
Abstract
Background: Randomized controlled trials can be expensive and time-consuming, leading to medical researchers utilizing real-world evidence (RWE) based on already-collected data. We aimed to conduct various RWE studies on angiotensin-converting enzyme inhibitors (ACEI) and angiotensin II receptor blocker (ARB), commonly used as firstline therapy for blood pressure, and to develop a multi-center clinical data mart (CDM) of ACEI/ARB for various clinical purposes. Methods: Data from electronic medical records of St. Mary’s Hospital and the Seoul National University Hospital were collected. We obtained blood and urine test results of patients within the 30 days prior to their first prescription of ACEI or ARB, as well as the first date of diagnosis and presence of various chronic and cardiovascular diseases using the International Classification of Diseases-10 classification. One researcher managed data quality and collation for each hospital in order to facilitate patient anonymity. When results were unclear, the responsible investigator for each hospital attempted to resolve ambiguities by direct chart review. Results: A total of 102,333 patients who were prescribed ACEI or ARB for the first time were included (21,481 ACEI, 80,551 ARB, and 301 both). Our ACEI/ARB-CDM included short-term studies (within 12 months) to observe changes in various blood or urinary laboratory test values after the initial prescription of ACEI or ARB and long-term studies to confirm the incidence of various diseases. Conclusion: We established a CDM of RWE for ACEI/ARB prescription, which included various clinical studies. As we accumulate experience in this process, we expect that the use of RWE research will grow and develop.
참고문헌 (27)
- Big Data: The next frontier for innovation, competition, and productivity, report, "McKinsey Global Institute (MGI)", ~ (2012)
- Garrison LP Jr, "Using realworld data for coverage and payment decisions : the ISPOR real-world data task force report", Value Health, 10(5), pp.326~335 (2007)
- Sherman RE, "Realworld evidence— what is it and what can it tell us?", N Engl J Med, 375, pp.2293~2297 (2016)
- Food and Drug Administration, "Use of real-world evidence to support regulatory decision-making for medical devices: draft guidance for industry and Food and Drug Administration staff", ~ (2016)
- 김헌성, "Real-world Evidence versus Randomized Controlled Trial: Clinical Research Based on Electronic Medical Records", Journal of Korean Medical Science, 33(34), pp.1~7 (2018), 대한의학회
- 송민구, "진료정보 분석 활용을 위한 Clinical DW에 관한 연구", 디지털융복합연구, 11(8), pp.293~302 (2013), 한국디지털정책학회
- 김철우, "전자의무기록 검색을 통한 중증 약물유해반응 선별", Allergy Asthma & Respiratory Disease, 6(3), pp.135~136 (2018), 대한 소아알레르기 호흡기학회[DOI]
- 김헌성, "Physician-Directed Diabetes Education without a Medication Change and Associated Patient Outcomes", Diabetes and Metabolism Journal, 41(3), pp.187~194 (2017), 대한당뇨병학회[DOI]
- 강동윤, "전자의무기록을 이용한 DRESS (drug reaction with eosinophilia and systemic symptoms) 증후군 탐색", Allergy Asthma & Respiratory Disease, 6(3), pp.149~154 (2018), 대한 소아알레르기 호흡기학회[DOI]
- Jeong YJ, "Analysis and comparison of the cost-effectiveness of statins according to the baseline low-density lipoprotein cholesterol level in Korea", J Clin Pharm Ther, 42(3), pp.292~300 (2017)
- Kim HC, "The Korean society hypertension (KSH), hypertension epidemiology research working group. Korea hypertension fact sheet 2018", Clin Hypertens, 24(13) (2018)
- 신진호, "2013 Korean Society of Hypertension guidelines for the management of hypertension. Part II—treatments of hypertension", Clinical Hypertension, 21(2), pp.1~13 (2015), 대한고혈압학회[DOI]
- Juhasz A, "Efficacy and safety of azilsartan medoxomil, an angiotensin receptor blocker, in Korean patients with essential hypertension", Clin Hypertens, 24(2) (2018)
- Liu M, "Albumin-to-creatinine ratio as a predictor of all-cause mortality and hospitalization of congestive heart failure in Chinese elder hypertensive patients with high cardiovascular risks", Clin Hypertens, 24, pp.12~ (2018)
- 김헌성, "Development of Clinical Data Mart of HMG-CoA Reductase Inhibitor for Varied Clinical Research", Endocrinology and Metabolism, 32(1), pp.90~98 (2017), 대한내분비학회
- Lee S, "Standard-based comprehensive detection of adverse drug reaction signals from nursing statements and laboratory results in electronic health records", J Am Med Inform Assoc, 24(4), pp.697~708 (2017)
- Kim HS, "Use of moderate-intensity statins for low-density lipoprotein cholesterol level above 190 mg", dL at baseline in Koreans, 2017, pp.121(4), 272~278
- Kim HS, "Analysis and comparison of statin prescription patterns and outcomes according to clinical department", J Clin Pharm Ther, 41(1), pp.70~77 (2016)
- Kim HS, "Comparative analysis of the suspected heparin-induced thrombocytopenia level in Korea", Basic Clin Pharmacol Toxicol, 121(4), pp.360~367 (2017)
- 홍주영, "Pilot Algorithm Designed to Help Early Detection of HMG-CoA Reductase Inhibitor-Induced Hepatotoxicity", Healthcare Informatics Research, 23(3), pp.199~207 (2017), 대한의료정보학회[DOI]
- Kim HS, "Statin-related aminotransferase elevation according to baseline aminotransferases level in real practice", J Clin Pharm Ther, 41(3), pp.266~272 (2016)
- Farmer R, "Promises and pitfalls of electronic health record analysis", Diabetologia, 61(6), pp.1241~1248 (2018)
- Kim TM, "The differences in the incidence of diabetes mellitus and prediabetes according to the type of HMG-CoA reductase inhibitors prescribed in Korean patients", Pharmacoepidemiol Drug Saf, 26(10), pp.1156~1163 (2017)
- 조금준, "의료 빅데이터를 활용한 임상 연구", Anesthesia and Pain Medicine, 12(1), pp.9~14 (2017), 대한마취통증의학회
- Corrigan-Curay J, "Real-World Evidence and Real-world data for evaluating drug safety and effectiveness", JAMA, 320(9), pp.867~868 (2018)
- Kim H, "Clinical experiences and case review of angiotensin II receptor blocker-related angioedema in Korea", Basic Clin Pharmacol Toxicol (2018)
- Wierzbicka N, "The evolving landscape for real world evidence in Poland : physicians' perspective", JHPOR, 1, pp.15~33 (2015)